Anaptysbio (ANAB) Capital Expenditures (QoQ) (2016 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Capital Expenditures (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Anaptysbio | 1.63 Bn | 1.34 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2,200.00% |
| Dec 31, 2025 | -91.67% |
| Sep 30, 2025 | -69.23% |
| Jun 30, 2025 | 11.43% |
| Mar 31, 2025 | -86.69% |
| Dec 31, 2024 | 651.43% |
| Sep 30, 2024 | 6.06% |
| Jun 30, 2024 | 22.22% |
| Mar 31, 2024 | -90.36% |
| Dec 31, 2023 | 72.84% |
| Sep 30, 2023 | -14.74% |
| Jun 30, 2023 | 8.57% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 250.00% |
| Sep 30, 2022 | -35.90% |
| Jun 30, 2022 | 41.82% |
| Mar 31, 2022 | 292.86% |
| Dec 31, 2021 | -91.86% |
| Sep 30, 2021 | -80.07% |
| Jun 30, 2021 | 172.24% |